Tissue Diagnostics Market by Product (Consumables, Instruments), Technology (Immunohistochemistry, in Situ Hybridization, Digital Pathology and Workflow), Disease (Breast Cancer, Gastric Cancer, Lymphoma), End User (Hospital, CRO) - Global Forecast to 2024

  • Report ID:MRHC - 104268
  • Pages: 122
  • Apr 2019
  • Formats*: PDF
  • Category: Healthcare

1 Introduction
   1.1 Market Definition
   1.2 Market Ecosystem
   1.3 Years Considered in the Study
   1.4 Currency & Limitations
   1.5 Key Stakeholders

2 Research Methodology
   2.1 Secondary Research
   2.2 Primary Research
   2.3 Market Size Estimation

3 Executive Summary

4 Market Insights
   4.1 Drivers
         4.1.1 Inflation in Cancer Patients
         4.1.2 Improving Infrastructure for Cancer Diagnosis
         4.1.3 Increasing Healthcare Expenditure
         4.1.4 Technological Advancements in Tissue Diagnostics
   4.2 Restraints
         4.2.1 Regulatory Framework Issues
         4.2.2 Limited Budgets
   4.3 Opportunities
         4.3.1 Rising Adoption of Personalized Medicine
         4.3.2 Rising Number of Clinical Trials for Cancer Drugs
         4.3.3 Growing Opportunities in Digital Pathology
         4.3.4 Emerging Economies
   4.4 Challenges
         4.4.1 Shortage of Qualified Pathologists
         4.4.2 Reimbursement Cuts
   4.5 Trends
         4.5.1 Increasing Number of Reagent Rental Contracts

5 Global Tissue Diagnostics Market, by Product
   5.1 Introduction
   5.2 Consumables
         5.2.1 Antibodies
         5.2.2 Kits
         5.2.3 Reagents
         5.2.4 Probes
   5.3 Instruments
         5.3.1 Slide-Staining Systems
         5.3.2 Scanners
         5.3.3 Tissue-Processing Systems
         5.3.4 Other Instruments

6 Global Tissue Diagnostics Market, by Technology
   6.1 Introduction
   6.2 Immunohistochemistry (IHC)
   6.3 in Situ Hybridization (ISH)
   6.4 Digital Pathology and Workflow Management
   6.5 H&E Slide Staining
   6.6 Special Staining

7 Global Tissue Diagnostics Market, by Disease
   7.1 Introduction
   7.2 Breast Cancer
   7.3 Gastric Cancer
   7.4 Prostrate Cancer
   7.5 Lung Cancer
   7.6 Lymphoma
   7.7 Non-Small Cell Lung Cancer (NSCLC)
   7.8 Other Diseases

8 Global Tissue Diagnostics Market, by End User
   8.1 Introduction
   8.2 Hospitals
   8.3 Research Laboratories
   8.4 Pharmaceutical Companies
   8.5 Contract Research Organizations
   8.6 Ambulatory Surgical Centers
   8.7 Other End Users

9 Global Tissue Diagnostics Market, by Geography
   9.1 North America
         9.1.1 U.S.
         9.1.2 Canada
   9.2 Europe
         9.2.1 Germany
         9.2.2 France
         9.2.3 U.K.
         9.2.4 Italy
         9.2.5 Spain
         9.2.6 Rest of Europe
   9.3 Asia-Pacific
         9.3.1 Japan
         9.3.2 China
         9.3.3 India
         9.3.4 Rest of Asia-Pacific
   9.4 Rest of the World
         9.4.1 Latin America
         9.4.2 Middle East & Africa

10 Global Tissue Diagnostics Market - Competitive Landscape
     10.1 Introduction
     10.2 Competitive Benchmarking
     10.3 Tissue Diagnostics Market Share Analysis

11 Company Profiles
     11.1 F. Hoffmann-La Roche Ltd
            11.1.1 Business Overview
            11.1.2 Financial Overview
            11.1.3 Product Portfolio
            11.1.4 Strategic Developments
     11.2 Danaher Corporation
            11.2.1 Business Overview
            11.2.2 Financial Overview
            11.2.3 Product Portfolio
            11.2.4 Strategic Developments
     11.3 Thermo Fisher Scientific Inc.
            11.3.1 Business Overview
            11.3.2 Financial Overview
            11.3.3 Product Portfolio
            11.3.4 Strategic Developments
     11.4 Abbott Laboratories
            11.4.1 Business Overview
            11.4.2 Financial Overview
            11.4.3 Product Portfolio
            11.4.4 Strategic Developments
     11.5 Agilent Technologies, Inc.
            11.5.1 Business Overview
            11.5.2 Financial Overview
            11.5.3 Product Portfolio
            11.5.4 Strategic Developments
     11.6 Merck KGaA (Sigma-Aldrich Co. LLC)
            11.6.1 Business Overview
            11.6.2 Financial Overview
            11.6.3 Product Portfolio
            11.6.4 Strategic Developments
     11.7 Sakura Finetek Japan Co., Ltd.
            11.7.1 Business Overview
            11.7.2 Financial Overview
            11.7.3 Product Portfolio
            11.7.4 Strategic Developments
     11.8 Abcam plc.
            11.8.1 Business Overview
            11.8.2 Financial Overview
            11.8.3 Product Portfolio
            11.8.4 Strategic Developments
     11.9 Becton, Dickinson, and Company (BD)
            11.9.1 Business Overview
            11.9.2 Financial Overview
            11.9.3 Product Portfolio
            11.9.4 Strategic Developments
     11.10 QIAGEN
              11.10.1 Business Overview
              11.10.2 Financial Overview
              11.10.3 Product Portfolio
              11.10.4 Strategic Developments
     11.11 Bio SB
              11.11.1 Business Overview
              11.11.2 Financial Overview
              11.11.3 Product Portfolio
              11.11.4 Strategic Developments
     11.12 BioGenex
              11.12.1 Business Overview
              11.12.2 Financial Overview
              11.12.3 Product Portfolio
              11.12.4 Strategic Developments
     11.13 Cell Signaling Technology, Inc.
              11.13.1 Business Overview
              11.13.2 Financial Overview
              11.13.3 Product Portfolio
              11.13.4 Strategic Developments
     11.14 3DHISTECH Ltd.
              11.14.1 Business Overview
              11.14.2 Financial Overview
              11.14.3 Product Portfolio
              11.14.4 Strategic Developments
     11.15 Cancer Genetics Inc.
              11.15.1 Business Overview
              11.15.2 Financial Overview
              11.15.3 Product Portfolio
              11.15.4 Strategic Developments

12 Appendix 
     12.1 Questionnaire

Tissue diagnostic techniques are majorly used to understand the preserved antigens in specific tissues. Tissue diagnostics involves monitoring, diagnosis, and management of different stages of cancer, especially breast cancer, prostate cancer, and gastric cancer, among others. Increasing prevalence of cancer, improving infrastructure for cancer diagnostics, increasing healthcare spending, and various technological advancements in tissue diagnostics field are the major factors fueling the growth of global tissue diagnostics market. 

As per the data from International Agency for Research on Cancer, the global number of cancer cases were 12.7 million in 2008, which increased to 18.1 million by September 2018. Thus, rising cancer cases and growing research funding for cancer treatment and improving healthcare infrastructure are likely to boost the demand for tissue diagnostics during the forecast period.

The tissue diagnostics market study presents in terms of value (2017 and 2018), estimated current data (2019), and forecasts for 2024 - by product, technology, disease, and end user. Furthermore, historical market data in terms of volume (2017 and 2018) and estimated current data (2019), and forecasts for 2024 is covered only for product segment. The study also evaluates industry competitors and analyzes their markets and there by estimating global, regional and country level.

Based on product, consumables commanded the largest share in 2018 over instruments. The large share of this segment is mainly attributed to extensive and recurring requirement of consumables and technological advances in the development of novel reagents and other consumables.

Based on technology, the tissue diagnostics market is segmented into immunohistochemistry, in situ hybridization, digital pathology & workflow management, H&E staining, and special staining. The immunohistochemistry segment accounted for the largest share of the global tissue diagnostics market in 2018. The growth in in vitro diagnostics and upsurge in the point of care diagnostics market is expected to fuel the growth of immunohistochemistry technology.

The report includes extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past 4 years (2015-2018). The tissue diagnostics market has witnessed number of new product launches in recent years. For instance, in January 2018, Roche launched CE-marked VENTANA MMR IHC Panel, which provides clinicians with a comprehensive group of immunohistochemistry (IHC) tests for patients diagnosed with colorectal cancer. The tests detect certain proteins associated with a DNA repair mechanism called mismatch repair (MMR), and aid in differentiating between sporadic colorectal cancer and probable Lynch syndrome, a hereditary form of colorectal cancer.

The tissue diagnostics market is highly competitive with the presence of players like F. Hoffmann-La Roche Ltd., Danaher Corporation, Thermo Fisher Scientific Inc., Abbott Laboratories, Agilent Technologies, Inc., Merck KGaA, Sakura Finetek Japan Co., Ltd., Abcam plc., Becton, Dickinson, and Company, QIAGEN, Bio SB, BioGenex, Cell Signaling Technology, Inc., 3DHISTECH Ltd., and Cancer Genetics Inc.

Future Outlook

In recent years, there has been an unprecedented expansion in the field of immunodiagnostics and nanomedicine, which have led to the emergence of potential diagnostics technologies. Also, innovation in diagnostic testing for highly efficient testing such as IHC, ISH, and other staining technologies would provide ample opportunities for players in the global tissue diagnostics market.

Report Name
Full Name
Email
Job Title
Company
Country
Phone Number
--
Your Specific Interest
Captcha
This website is secure and we do not share your personal information with any third party. Privacy Policy
Tags: Healthcare Biotechnology Assays Reagents & Kits Automated Instrumentation Clinical Chemistry Analytical Instrumentation Imaging Technologies Immunoassays
Download Free Sample